Clinical trials
Clinical Study clinical trials
Below are recruiting clinical study clinical trials, each written for real people, not researchers. We’re tracking 1,811 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07107633RecruitingPhase 2
Imaging test for cancer spread in the abdomen
This trial tests a special imaging injection to see if it can better detect cancer that has spread to the lining of the abdomen in people with stomach or bowel cancer. If you are scheduled for surgery to remove or explore the cancer, this scan might help your doctor plan the best treatment.
ShanghaiAges 18 years+ - NCT07308106RecruitingPhase 2
Testing SKB571 for MET-mutated advanced lung cancer
This trial tests a new drug called SKB571 for people with advanced lung cancer that has a specific change in the MET gene. The goal is to see if the drug can shrink tumors or stop them from growing.
ShanghaiAges 18–75 - NCT07496164Recruiting
Testing three new denture adhesives against no adhesive
This study tests whether three new denture adhesives help people who have a full upper denture (false teeth on the top) and some natural or false teeth on the bottom. You will try each adhesive and also a period with no adhesive to see how well your denture stays in place.
Indianapolis, IndianaAges 18 years+ - NCT07493239Recruiting
Testing a supplement for knee pain and mobility
This trial studies whether a dietary supplement called MyCondro™ can improve joint health and movement in people with knee osteoarthritis. You will take the supplement for up to 16 weeks and track your symptoms using a smartphone app.
Los Angeles, CaliforniaAges 45 years+ - NCT06349629Recruiting
Testing a new dissolving metal implant for joint fractures
This trial tests a new 3D-printed metal implant made of a special magnesium alloy that dissolves over time. It is designed to help mend broken bones near joints, such as wrist, shoulder, or knee fractures, where there is a missing piece of bone.
Beijing, HaidianAges 18–80 - NCT05955768Enrolling by invitation
Lidocaine in a cervical dilator to reduce removal pain
This study tests whether putting lidocaine (a numbing medicine) into a disposable cervical dilator can reduce pain during uterine device removal done with local anesthesia. If you’re eligible, your experience of pain is measured so researchers can compare comfort between study procedures.
Hangzhou, ZhejiangAges 18–65 - NCT07477743RecruitingPhase 1
Study of a new drug combo for advanced solid tumors
This trial tests a new combination treatment (HC010) for people with advanced solid tumors that have spread or cannot be removed by surgery. It aims to see if the drug is safe and effective.
BeijingAges 18–75 - NCT07123207Recruiting
Probiotic with infliximab for Crohn's disease
This study is testing whether adding a probiotic (Bacillus subtilis) to standard infliximab treatment can improve outcomes for people with active Crohn's disease. It aims to see if the probiotic helps the medication work better.
Changsha, HunanAges 18–75 - NCT05978102RecruitingPhase 1/Phase 2
Study of STI-7349 for advanced solid cancers
This early-phase study tests STI-7349 (a new cancer treatment) in people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see how well it can control cancer.
Yiwu, ZhejiangAges 18–80 - NCT05653453RecruitingPhase 3
Tumor treatment device plus chemo for locally advanced pancreatic cancer
This trial tests whether a home-wearable tumor-treating device (Tumor Treating Fields) combined with gemcitabine and albumin-bound paclitaxel works better as first treatment for locally advanced pancreatic cancer. It may help by targeting cancer cells while also using standard chemotherapy.
Harbin, HeilongjiangAges 18–75 - NCT07459751RecruitingPhase 2/Phase 3
A study of HLX43 alone or with HLX07 vs docetaxel for advanced squamous lung cancer
This trial tests a new drug called HLX43, given alone or with HLX07, against the standard chemo docetaxel for people with a type of advanced lung cancer called squamous non-small cell lung cancer. It's for patients who have already tried and not responded to platinum chemo and immunotherapy.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07044921RecruitingPhase 2
Irinotecan liposome combination for advanced colorectal cancer
This trial tests a new combination treatment for people with advanced colorectal cancer whose cancer has stopped responding to irinotecan. The goal is to see if adding a liposome form of irinotecan to other drugs can help shrink tumors or slow the disease.
BeijingAges 18 years+ - NCT06671275Enrolling by invitationPhase 1
Testing CUD005 Injection for Advanced Liver Cirrhosis
This study tests an injection called CUD005 for people with advanced liver cirrhosis that is causing complications. The goal is to see if it is safe and can help improve liver function.
Hefei, AnhuiAges 18–75 - NCT06383871RecruitingPhase 1
A study of the new drug HRS-7058 for advanced solid tumors
This is a phase 1 study testing a new oral drug called HRS-7058 for people with advanced solid tumors that have not responded to other treatments. The main goal is to find a safe dose and see how well the drug works.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT07416240RecruitingEarly Phase 1
Targeted immune cell therapy for Claudin18.2-positive advanced pancreatic cancer
This early-phase trial is testing a new kind of immune cell therapy—dendritic cells and CAR-T cells—that specifically targets a protein called Claudin18.2 on your cancer cells. It is for people with advanced pancreatic cancer who have already tried standard treatments.
Haikou, HainanAges 18–80 - NCT06735144RecruitingPhase 1/Phase 2
Testing FH-006 for advanced solid tumors
This trial tests a new drug called FH-006 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective.
Guangzhou, GuangdongAges 18–75 - NCT06735391RecruitingPhase 3
JMT101 plus osimertinib vs osimertinib for EGFR-mutant lung cancer
This trial tests a new combination of two targeted drugs (JMT101 and osimertinib) against osimertinib alone for people with advanced lung cancer that has an EGFR mutation. The goal is to see if the combination works better as a first treatment.
GuangzhouAges 18 years+ - NCT06743477Recruiting
Super transplant for severe thalassemia in children
This trial tests a new type of transplant (called 'super transplantation') for children with severe thalassemia. It aims to help those who cannot get a fully matched donor or have chosen not to have standard treatments.
Kunming, YunnanAges 7–12 - NCT07070674RecruitingPhase 1
Study of AC-003 for steroid-resistant graft-versus-host disease
This trial tests an experimental capsule (AC-003) for people with graft-versus-host disease (aGVHD) after a stem cell transplant, whose aGVHD did not get better with steroids. The goal is to see if it can help control the condition.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07068932RecruitingPhase 1
Study of SHR-4506 for advanced solid tumors
This trial tests a new drug, SHR-4506, for people with advanced cancers that have stopped responding to standard treatments or cannot be treated with standard options. It aims to see if the drug is safe and helpful.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06074679Recruiting
Single incision gallbladder surgery for acute cholecystitis
This study tests whether removing the gallbladder through a single small cut (single incision laparoscopic cholecystectomy) is safe and effective for people with acute cholecystitis (sudden gallbladder inflammation). It may mean less pain and faster recovery than traditional surgery.
Huangshan City, AnhuiAges 18–70 - NCT06306456RecruitingPhase 1/Phase 2
GH21 combined with osimertinib for advanced lung cancer
This trial tests a new drug (GH21) combined with the targeted therapy osimertinib (Tagrisso) for people with advanced non-small cell lung cancer that has an EGFR mutation and has stopped responding to a similar treatment. The goal is to see if the combination can help when the cancer has progressed.
Hefei, AnhuiAges 18 years+ - NCT07269145RecruitingPhase 1
Testing TQB3122 capsules in advanced solid tumors
This trial tests an experimental oral capsule (TQB3122) for safety and early signs of effectiveness in people with advanced solid tumors that have not responded to standard therapies. It is for patients who are relatively healthy and have specific cancer types like ovarian, breast, or prostate cancer.
Beijing, Beijing MunicipalityAges 18–75 - NCT07025304Recruiting
Study of REFLEX ULTRA 45 for nasal turbinate reduction in China
This trial tests a new device called REFLEX ULTRA 45 that uses radiofrequency energy to shrink the nasal turbinates (the fleshy shelves inside your nose) to help you breathe easier. It is for people with long-term nasal stuffiness who have not gotten relief from nasal sprays.
Guangzhou, GuangdongAges 18–65
Hear when a new Clinical Study trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for clinical study?
- Yes. Clin2 currently lists 1,811 recruiting clinical study studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a clinical study trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a clinical study trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.